Bioventus financials
$14.00−0.14%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 27 | Q1 '26 Mar 28 | Q4 '25 Dec 31 | Q3 '25 Sep 27 | Q2 '25 Jun 28 | Q1 '25 Mar 29 | Q4 '24 Dec 31 | Q3 '24 Sep 28 | Q2 '24 Jun 29 | Q1 '24 Mar 30 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $153.2M | $132.1M | $157.9M | $138.7M | $147.7M | $123.9M | $153.6M | $139.0M | $151.2M | $129.5M | $135.4M | $120.8M |
| Gross profit | $105.7M | $90.8M | $108.8M | $94.2M | $102.1M | $83.1M | $102.7M | $93.6M | $103.6M | $88.4M | $86.3M | $78.8M |
| Gross margin | 69.0% | 68.7% | 68.9% | 68.0% | 69.1% | 67.0% | 66.8% | 67.3% | 68.5% | 68.3% | 63.7% | 65.3% |
| Operating income | $19.1M | $8.4M | $19.5M | $11.3M | $18.4M | $5.0M | $10.5M | $5.7M | $397.0K | $4.9M | $2.4M | $3.8M |
| Net income | $36.2M | $3.1M | $14.8M | $3.2M | $9.3M | -$2.6M | -$388.0K | -$5.2M | -$25.7M | -$4.9M | -$6.1M | -$7.3M |
| Net margin | 23.6% | 2.4% | 9.3% | 2.3% | 6.3% | −2.1% | −0.3% | −3.7% | −17.0% | −3.8% | −4.5% | −6.0% |
| Diluted EPS | $0.47 | $0.04 | $0.20 | $0.05 | $0.11 | $-0.04 | $-0.01 | $-0.08 | $-0.40 | $-0.08 | $-0.10 | $-0.12 |
| EBITDA | $29.7M | $20.1M | $33.4M | $22.7M | $30.4M | $16.8M | $22.8M | $18.0M | $13.5M | $17.0M | $3.0M | $17.6M |
| Operating cash flow | $19.9M | $8.9M | $38.0M | $30.1M | $25.9M | -$19.3M | $19.3M | $10.3M | $15.2M | -$6.0M | $10.8M | -$8.2M |
| Free cash flow | $18.9M | $8.4M | $37.4M | $29.6M | $25.3M | -$20.2M | $18.7M | $10.3M | $15.1M | -$6.3M | $10.4M | -$10.3M |
| Diluted shares | 70.8M | 70.0M | 72.3M | 68.8M | 68.5M | 66.0M | 65.5M | 65.3M | 64.1M | 63.4M | 63.1M | 62.8M |
Balance sheet
| Period end | Jun 27 | Mar 28 | Dec 31 | Sep 27 | Jun 28 | Mar 29 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $29.5M | $35.8M | $51.2M | $42.2M | $32.9M | $22.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $248.5M | $272.1M | $294.0M | $322.6M | $341.2M | $345.9M |
| Total assets | $673.3M | $650.5M | $683.6M | $701.6M | $706.8M | $691.4M |
| Total liabilities | $395.9M | $416.3M | $455.1M | $494.3M | $505.5M | $505.9M |
| Shareholders' equity | $277.4M | $234.3M | $228.4M | $207.3M | $201.3M | $185.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology